Forbes

Johnson & Johnson Vaccine’s 66% Efficacy Figure Is Better Than It Looks

Johnson & Johnson announced that its single-shot Covid-19 vaccine was 66% effective in preventing moderate and severe cases of Covid-19 in its global phase 3 trials. Efficacy varied by region, with the shot proving 72% effective in the U.S., 66% effective in Latin America, and around 57% effective..

Source: Forbes – Markets
Date: February 2, 2021, 14:57